DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS (Details) $ / shares in Units, $ in Thousands		1 Months Ended	12 Months Ended
	Jul. 21, 2023 USD ($) $ / shares shares	Oct. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) $ / shares shares	Jul. 31, 2023 participant	Jun. 30, 2023 participant patient	Dec. 31, 2022 USD ($) $ / shares
Subsidiary, Sale of Stock [Line Items]
Common stock, par value (in dollars per share) | $ / shares			$ 0.0001			$ 0.0001
Accumulated deficit			$ 222,798			$ 170,427
Working capital			233,600			$ 172,500
Proceeds from term loan, net			$ 29,500
Number of patients enrolled in trail | patient					65
Number of patients enrolled in trial with one dose of study drug received | participant					62
Number of participants enrolled in trial with one dose of study drug received with primary and secondary objectives met | participant				62
Public Offering
Subsidiary, Sale of Stock [Line Items]
Sale of stock, number of shares issued in transaction (in shares) | shares	16,774,193
Common stock, par value (in dollars per share) | $ / shares	$ 0.0001
Sale of stock, price per share (in dollars per share) | $ / shares	$ 7.75
Sale of stock, consideration received on transaction	$ 121,900
At The Market Offering
Subsidiary, Sale of Stock [Line Items]
Sale of stock, number of shares issued in transaction (in shares) | shares		422,160	0
Sale of stock, price per share (in dollars per share) | $ / shares		$ 10.06
Sale of stock, consideration received on transaction		$ 3,800